301 results on '"McMeekin, D. Scott"'
Search Results
2. A phase 1b dose escalation study of ipafricept (OMP[sbnd]54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer
3. The pro-inflammatory effect of obesity on high grade serous ovarian cancer
4. Primary and acquired platinum-resistance among women with high grade serous ovarian cancer
5. Initiation of a formalized precision medicine program in gynecologic oncology
6. Preface
7. Contributors
8. Sarcoma of the Uterus
9. A phase I study of IV doxorubicin plus intraperitoneal (IP) paclitaxel and IV or IP cisplatin in endometrial cancer patients at high risk for peritoneal failure (GOG 9920): An NRG Oncology/Gynecologic Oncology Group study
10. A phase II trial of brivanib in recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group Study
11. The survival detriment of venous thromboembolism with epithelial ovarian cancer
12. Measurements of adiposity as clinical biomarkers for first-line bevacizumab-based chemotherapy in epithelial ovarian cancer
13. Phase II trial of vaginal cuff brachytherapy followed by chemotherapy in early stage endometrial cancer patients with high-intermediate risk factors
14. Referrals to phase I clinical trials in a gynecologic oncology unit
15. Dynamic Contrast-Enhanced MR Imaging for Predicting Tumor Control in Patients with Cervical Cancer
16. Inpatient versus outpatient management of neutropenic fever in gynecologic oncology patients: Is risk stratification useful?
17. Etiologic heterogeneity in endometrial cancer: Evidence from a Gynecologic Oncology Group trial
18. Nonsteroidal Anti-inflammatory Drugs and Endometrial Carcinoma Mortality and Recurrence
19. A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: A Gynecologic Oncology Group study
20. A phase II trial of thalidomide in patients with refractory uterine carcinosarcoma and correlation with biomarkers of angiogenesis: A Gynecologic Oncology Group study
21. A phase I study of concurrent weekly topotecan and cisplatin chemotherapy with whole pelvic radiation therapy in locally advanced cervical cancer: A gynecologic oncology group study
22. Relationships of Tubal Ligation to Endometrial Carcinoma Stage and Mortality in the NRG Oncology/Gynecologic Oncology Group 210 Trial
23. Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study
24. Phase II trial of intraperitoneal cisplatin combined with intravenous paclitaxel in patients with ovarian, primary peritoneal and fallopian tube cancer
25. A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: A Gynecologic Oncology Group Study
26. Targeted therapies for gynecologic malignancies
27. Endometrial cancer: Treatment of nodal metastases
28. Preface
29. The Adnexal Mass
30. Sarcoma of the Uterus
31. Contributors
32. Sarcoma of the Uterus
33. Contributors
34. Does the progression-free interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer? A gynecologic oncology group ancillary data analysis
35. Dynamic Contrast-Enhanced MR Imaging for Predicting Tumor Control in Patients with Cervical Cancer
36. Ultra-early predictive assay for treatment failure using functional magnetic resonance imaging and clinical prognostic parameters in cervical cancer
37. Role of pegylated liposomal doxorubicin in ovarian cancer
38. Adjuvant chemotherapy for the 'oldest old' ovarian cancer patients: can we anticipate toxicity-related treatment failure in a vulnerable population?
39. Consolidation therapy in ovarian cancer: where do we stand?
40. Timing isn't everything: an analysis of when to start salvage chemotherapy in ovarian cancer
41. A comparison of stages IB1 and IB2 cervical cancers treated with radical hysterectomy. Is size the real difference?
42. Patients With Malignancy Requiring Urgent Therapy: CASE 3. Tumor Lysis Syndrome Associated With Chemotherapy in Ovarian Cancer
43. Randomized Phase III Trial of Cisplatin With or Without Topotecan in Carcinoma of the Uterine Cervix: A Gynecologic Oncology Group Study
44. 6 - Sarcoma of the Uterus
45. Phase II evaluation of Three-Day topotecan in recurrent platinum-sensitive ovarian carcinoma
46. A phase 1b dose escalation study of ipafricept (OMP 54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer
47. Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early-Stage Endometrial Cancer
48. Nonsteroidal Anti-inflammatory Drugs and Endometrial Carcinoma Mortality and Recurrence
49. Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study
50. Phase 1b of WNT inhibitor ipafricept (IPA, decoy receptor for WNT ligands) with carboplatin (C) and paclitaxel (P) in recurrent platinum-sensitive ovarian cancer (OC).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.